SCHEMBL1781812

SCHEMBL1781812

O=C(O)c1ccccc1C(=O)NCl

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.64
ALOX15 P16050 1/20 0.64
KMT2A Q03164 4/20 0.55
APEX1 P27695 1/20 0.55
CYP1A2 P05177 2/20 0.55
CYP3A4 P08684 2/20 0.55
GAA P10253 2/20 0.55
ALOX12 P18054 2/20 0.55
CYP2C19 P33261 1/20 0.55
MAPT P10636 3/20 0.52
POLB P06746 1/20 0.52
KDM4E B2RXH2 3/20 0.50
MEN1 O00255 2/20 0.50
HPGD P15428 2/20 0.50
AKR1C3 P42330 1/20 0.50
CYP2C9 P11712 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
LMNA P02545 1/20 0.49
TAAR1 Q96RJ0 1/20 0.49
CA12 O43570 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30930714 0.91 POLB (0.50) ALDH1A1ALOX15KMT2AAPEX1CYP1A2
SCHEMBL11700974 0.81 ALDH1A1 (0.71) ALDH1A1ALOX15KMT2AAPEX1CYP1A2
SCHEMBL9849005 0.81 AKR1C3 (0.61) ALDH1A1KMT2AGAAMAPTMEN1
SCHEMBL4121945 0.80 KDM4E (0.50) ALDH1A1KMT2AGAAMAPTPOLB
Phthalic Acid SCHEMBL1686043 0.80 ALDH1A1 (1.00) ALDH1A1ALOX15MAPTPOLBKDM4E
Phthalic Acid SCHEMBL5668586 0.80 ALDH1A1 (1.00) ALDH1A1ALOX15MAPTPOLBKDM4E
Phthalic Acid SCHEMBL146125 0.80 ALDH1A1 (1.00) ALDH1A1ALOX15MAPTPOLBKDM4E
Phthalic Acid SCHEMBL1808 0.80 ALDH1A1 (1.00) ALDH1A1ALOX15MAPTPOLBKDM4E
Phthalic Acid SCHEMBL1332278 0.80 ALDH1A1 (1.00) ALDH1A1ALOX15MAPTPOLBKDM4E
Phthalic Acid SCHEMBL4452470 0.80 ALDH1A1 (1.00) ALDH1A1ALOX15MAPTPOLBKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4250063-A COORDINATION CATALYST COMPRISING AN ORGANIC COMPLEX OF TUNGSTEN OR MOLYBDENUM, A TITANIUM TETRAHALIDE, AND AN N-HALO IMIDE, A SULFIDE, A SULFOXIDE, OR A PHOSPHINE; POLYALKENAMERS JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1981-02-10 US claimed
US-4233459-A TREATED WITH REDUCING AGENTS IN TWO STEPS DURING OR AFTER PREPARATION FROM ALKALI METAL PHTHALAMATE OR PHTHALIMIDATE AND AN ALKALI METAL HYPOHALITE BASF AKTIENGESELLSCHAFT (DE) 1980-11-11 US claimed
CN-119874611-A Process for preparing benzyl 4-amino-3-chloro-5-fluoro-6- (4-chloro-2-fluoro-3-methoxyphenyl) picolinate 科迪华农业科技有限责任公司 2025-04-25 CN disclosed
CN-110088107-A Compounds, compositions and uses thereof 赛诺维信制药公司 2019-08-02 CN disclosed
US-8779137-B2 Compound and organic electroluminescent element using the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-07-15 US disclosed
US-20120286654-A1 COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-11-15 US disclosed
EP-2520576-A1 COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT USING SAID COMPOUND Sumitomo Chemical Company, Limited (JP) 2012-11-07 EP disclosed
US-20110114185-A1 PHOTOELECTRIC CONVERSION ELEMENT SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-05-19 US disclosed
EP-0054677-A2 Cephalosporins, process for their preparation and pharmaceutical compositions containing them Dr. Karl Thomae GmbH (DE) 1982-06-30 EP disclosed
EP-0004635-B1 PROCESS FOR THE CONTINUOUS PREPARATION OF ANTHRANILIC ACID BASF Aktiengesellschaft (DE) 1981-08-12 EP disclosed
US-4276433-A Continuous preparation of anthranilic acid BASF AKTIENGESELLSCHAFT (DE) 1981-06-30 US disclosed
US-4250063-A COORDINATION CATALYST COMPRISING AN ORGANIC COMPLEX OF TUNGSTEN OR MOLYBDENUM, A TITANIUM TETRAHALIDE, AND AN N-HALO IMIDE, A SULFIDE, A SULFOXIDE, OR A PHOSPHINE; POLYALKENAMERS JAPAN SYNTHETIC RUBBER CO., LTD. (JP) 1981-02-10 US disclosed
EP-0003053-B1 PROCESS FOR THE CONTINUOUS PREPARATION OF ANTHRANILIC ACID BASF Aktiengesellschaft (DE) 1980-11-26 EP disclosed
US-4233459-A TREATED WITH REDUCING AGENTS IN TWO STEPS DURING OR AFTER PREPARATION FROM ALKALI METAL PHTHALAMATE OR PHTHALIMIDATE AND AN ALKALI METAL HYPOHALITE BASF AKTIENGESELLSCHAFT (DE) 1980-11-11 US disclosed
EP-0004635-A2 Process for the continuous preparation of anthranilic acid BASF Aktiengesellschaft (DE) 1979-10-17 EP disclosed
EP-0003053-A1 Process for the continuous preparation of anthranilic acid BASF Aktiengesellschaft (DE) 1979-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120286654-A1 COMPOUND AND ORGANIC ELECTROLUMINESCENT ELEMENT USING THE SAME ETV6, RPL19, LEF1 ALDH1A1 1210/4885ALOX15 206/4885KMT2A 2188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.